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Abstract 
Resistance to artemisinin derivatives (ARTs) in malaria disease is currently defined as a delayed parasite clearance following artemisinin 
combined therapy (ACT). Although ACT is still widely effective, the first evidence of artemisinin resistance was described in 2009 in 
Southeast Asia. Since then, resistance to ARTs / ACT has been monitored showing an increasing trend. The demonstrated resistance to all 
drugs that are currently associated to ART, the ambiguous finding that ART resistance is observed only in presence of resistance to the 
partner drug, the lack of a mechanistic rationale to choose the partner drugs and the lack of markers with known specificity and sensitivity to 
monitor ART resistance, represent the most worrisome issues. 
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Introduction 
Worldwide introduction of artemisinin derivatives 
(ART) improved the effectiveness of this therapy both 
in uncomplicated and in severe malaria saving a large 
number of lives and leading to a net reduction of 
prevalence in many countries. Natural products 
containing ART have been used in China and in 
malaria endemic European regions such as Sardinia 
since centuries; although high rates of recrudescence 
after ARTs treatment (from 4% to 30%) have been 
repeatedly reported [1-5], the evidence of ARTs 
resistance has only recently been outlined. As a matter 
of fact, ART resistance, defined as a delayed clearance 
of parasites (DPC) after therapy, has been observed on 
the Thailand/Cambodia border in 2009 and correlated 
to higher recrudescence rates in a small cohort of 
patients [6]. Currently, evidences of artemisinin 
resistance have been identified in many countries of 
Southeast Asia such as at the border between 
Myanmar and India. Despite a demonstrable increase 
of DPC prevalence in this region, patients generally 
respond to artemisinin combinatory therapies (ACT). 
Notably, in these areas the resistance to combinatory 
drugs is often present and the risk of developing multi-
drug resistance is therefore substantial [7]. 
It is our opinion that the management of ART 
resistance is particularly troublesome because of two 
major issues: (i) lack of markers for epidemiological 
and diagnostic uses; (ii) lack of drugs with proven 
synergism to ART or at least with no negative 
interactions. 
 
Markers of artemisinin resistance 
It is very difficult to isolate artemisinin resistant 
strains from patients with a demonstrable therapeutic 
failure; since no laboratory markers with known 
sensitivity and specificity are available, it is important 
to underline that the assessment of ART resistance is 
more complex and more prone to errors than in the 
case of any other antimalarial drugs. 
Among the available markers of ART resistance 
the measurement of ART IC50 or estimates of the time 
required by ART to kill parasites in short term ex vivo 
cultures can provide information; however, these 
assays need a stringent inter-laboratory standardization 
and are easily affected by the inconsistent adaptation 
of parasite to culture conditions [7]. 
An additional limit is posed by the difficulty to 
discriminate between recrudescence due to: 
(ii) therapeutic failure to ARTs, (ii) therapeutic 
failure to the partner drug; (iii) re-infection; (iv) 
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inadequate drug uptake/absorption. To discriminate 
between therapeutic failure and re-infection is clearly 
more difficult in areas with high prevalence and low 
seasonality of malaria. 
The finding and the validation of new markers to 
diagnose ART resistance is therefore mandatory, but 
the fact that the mechanism of action of ART is nearly 
unknown [8] and ART-resistant strains isolated from 
patients are generally not available represent a clear 
disadvantage. As the search of new markers cannot be 
based on a definite rationale, DPC (in vivo and in 
vitro) still represents the golden standard, although its 
sensitivity and specificity is still undetermined. 
More recently, a mutation on the K13-Propeller 
locus has been observed to be associated to DPC in 
Cambodia [9]; subsequently, additional mutations on 
the same gene have been observed in other regions in 
South Asia [10-16]. This promising marker is 
currently used in association with DPC to identify 
ART resistance but both still require a substantial 
clinical validation. Wide clinical trials to correlate 
DPC and K13 mutations with confirmed ART 
resistance are therefore needed to assess the isolated 
and cumulative performances of the markers [16]. 
Unfortunately the intrinsic complexity of those 
markers do not favor the sustainability and the 
implementation of the large clinical trials that should 
be required to validate and to assign precise 
performances to available makers. Table 1 outlines the 
current state of the technical tools available to estimate 




Drugs for combinatory therapy 
Following the alarming evidence on the possible 
spreading of ART resistant strains, the use of 
combinatory ART therapy (ACT) has been strongly 
advised by health authorities and it is now widely 
used. Lack of information on the mechanism of action 
of ART, however, limits again a rational choice of the 
partner drug; and possible negative interferences 
between drugs cannot be excluded [16]. This issue is 
even more relevant as most of the available anti-
malarial drugs already displayed manifest resistance 
[17] and as ART resistance is observed only in 
presence of a demonstrated resistance to the partner 
drug [7]. The observation that ART activity is 
functionally related to the hemoglobin metabolism of 
the parasite poses further concern on the choice of the 
partner drug as 4-aminoquinolinic compounds 
interfere with this pathway and have showed negative 
interaction in vitro [18].  Table 2 displays the ACT 
therapies currently in use. 
In conclusion, the emergence of a clinically 
relevant ART resistance may easily harm the recent 
advances obtained in the cure and control of malaria. 
Differently to the resistance observed for other anti-
malarial drugs, ART resistance appears subtle and 
particularly difficult to assess due to the lack of clear-
cut clinical counterparts and specific diagnostic tools. 
Currently, observational studies to monitor the rate of 
recrudescence taking in account the rates of 
spontaneous infection and the frequency of 
asymptomatic carriers are urgently needed to ensure 
the effectiveness of different therapeutic regimens and 
clinical validation of available markers. 
 
Table 1. Technical tools to estimate ART resistance 
Markers Sensitivity/Specificity Notes 
Parasitemia at day 28  High sensitivity 
Specificity may be affected by false positive results 
due to re-infection 
DPC at 3, 5 days in vivo  Not available No clinical studies are available to determine their 
diagnostic performances   K13 mutations Not available 
 
 
Table 2. ACT types currently used in South East Asia 
Country 
ACT type (2015) 
Artemether - Lumefantrine Artesunate-Mefloquine DHA-Piperaquine 
Cambodia ------ √ √ 
Laos √ ------ ------ 
Myanmar √ √ √ 
Thailand √ √ ------- 
Vietnam ------ ------ √ 
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